FDA, FTC collaborate to deter anti-competitive practices involving biosimilars

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA and the Federal Trade Commission signed a joint statement Feb. 3 on enhanced collaboration in support of a robust marketplace for biological products, including the critical adoption of biosimilars and interchangeable products.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login